Drug Search Results
More Filters [+]

Taliglucerase alfa

Alternative Names: taliglucerase alfa, elelyso, prgcd
Latest Update: 2024-06-13
Latest Update Note: News Article

Product Description

an enzyme replacement therapy using plant cell expression technology. aliglucerase alfa is a plant cell-expressed acid β-glucosidase approved in the United States and other countries for ERT in adults with GD1. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24630271/)

Mechanisms of Action: Glucocerebroside Hydrolyzer

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Brazil | Canada | Chile | Dominican Republic | European Medicines Agency | Israel | New Zealand | Peru | Russia | Serbia | South Africa | Taiwan | Turkey | Ukraine | United States | Uruguay

Approved Indications: Gaucher Disease

Known Adverse Events: Back Pain | Headache | Pain Unspecified | Nasopharyngitis | Pharyngitis | Arthralgia | Influenza, Human

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Taliglucerase alfa

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events